Melasma
☆ Na nsonaazụ Stiftung Warentest nke 2022 sitere na Germany, afọ ojuju ndị ahịa na ModelDerm dị ntakịrị ntakịrị karịa na nyocha telemedicine akwụ ụgwọ.
Ọ bụ ọnọdụ a na-ahụkarị na ụmụ nwanyị Eshia na mmalite afọ 40 ha. Ọnya gbara okirikiri dị na foto a dị nso na lentigo karịa melasma.
References
Tranexamic acid is a novel treatment option for melasma; however, there is no consensus on its use. This systematic review searched major databases for relevant publications to March 2016. Eleven studies with 667 participants were included. Pooled data from tranexamic acid-only observational studies with pre- and post-treatment Melasma Area and Severity Index (MASI) showed a decrease of 1.60 in MASI after treat?ment with tranexamic acid. The addition of tranexamic acid to routine treatment modalities resulted in a further decrease in MASI of 0.94. These results support the efficacy and safety of tranexamic acid, either alone or as an adjuvant to routine treatment modalities for melasma.
N'oge na-adịbeghị anya, low-fluence Q-switched Nd:YAG (LFQSNY) laser aghọwo ihe a ma ama maka ịgwọ ọrịa melasma, karịsịa na Eshia. Ịchịkọta ọmụmụ ihe dị iche iche bụ ihe ịma aka, mana LFQSNY yiri ka ọ dị irè ma dị mma maka melasma ma e jiri ya tụnyere usoro ọgwụgwọ ọdịnala. Otú ọ dị, a kọwo ụfọdụ ọnọdụ nke hypopigmentation mottled dị ka mmetụta dị n'akụkụ nke LFQSNY, ikekwe n'ihi ike laser dị elu. Iji ike eme ihe nke LFQSNY nwekwara ike ibute hyperpigmentation site na mbufụt, ọkachasị na ụda akpụkpọ ahụ gbara ọchịchịrị.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
A na-ahụkarị nsogbu pigmentation na nlekọta mbụ. Ụdị nsogbu hyperpigmentation a na-ahụkarị gụnyere post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Enweghị ike idozi Melasma na ọgwụgwọ laser ruo oge ụfọdụ, n'ihi na ọ bụ ọrịa nke a na-emepụta pigmenti mgbe niile. Traxenemic acid na-enyere aka melite iji belata pigmenti.
○ Ọgwụgwọ
Na mba ụfọdụ (dịka ọmụmaatụ, Japan, Korea), tranexamic acid nke ọnụ dị n'elu counter ma dị irè. Ude melasma nwere tranexamic acid na azelaic acid nwere ike inye aka n'otu akụkụ.
Enwere ike iji Hydroquinone mee ihe maka ọgwụgwọ hyperpigmentation, mana FDA kwụsịrị ngwaahịa OTC nwere hydroquinone dị ka nke 2020.
#Tranexamic acid [TRANSINO]
#Laser toning technique (low fluence QS1064 laser)
#Triluma